Finance

Lists
Outlook: 18.2% bullish·13.6% bearish
Go to analysis
HLN:NYSE
Haleon PLC - ADR
$8.84
+0.80%
(+0.070) 1D
Nov 3, 11:18:53 AM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for HLN...
Open
$8.87
High
$8.93
Low
$8.82
Mkt. cap
38.42B
Avg. vol.
20.34M
Volume
12.14M
Dividend
2.24%
Quarterly dividend
$0.05
Ex-dividend date
Aug 13, 2026
P/E ratio
18.21
52-wk high
$11.28
52-wk low
$8.38
EPS
$0.49
Beta
0.17
Shares outstanding
4.40B
No. of employees
25K
Open
$8.87
High
$8.93
Low
$8.82
Mkt. cap
38.42B
Avg. vol.
20.34M
Volume
12.14M
Dividend
2.24%
Quarterly dividend
$0.05
Ex-dividend date
Aug 13, 2026
P/E ratio
18.21
52-wk high
$11.28
52-wk low
$8.38
EPS
$0.49
Beta
0.17
Shares outstanding
4.40B
No. of employees
25K
News stories
From web sources and news partners
Profile
Haleon plc is a British multinational consumer healthcare company with headquarters in Weybridge, England. It is one of the largest consumer healthcare businesses in the world, with brands including Sensodyne toothpaste, Panadol and Advil painkillers, and Centrum vitamins. The company was projected to be a global leader in over the counter medicines with a 7.3 per cent market share in 2022. Haleon was established on 18 July 2022 as a corporate spin-off from GSK. Haleon is listed on the London Stock Exchange and is a component of the FTSE 100, with a secondary listing on the New York Stock Exchange. Wikipedia
About Haleon PLC - ADR
CEO-
Employees24.5K
FoundedJul 18, 2022
Headquarters-
SectorPharmaceutical industry
Websitehaleon.com
Analyst ratings
Based on 2 analysts giving stock ratings to HLN in the past 3 months
Buy
Buy
2
Hold
0
Sell
0
12-month forecast
Based on 2 Wall Street analysts offering 12 month price targets for HLN in the last 3 months.
Highest
Current $8.84
$12.40 (+40.19%)
Average
$11.70 (+32.28%)
Lowest
$11.00 (+24.36%)
Analyst
Recommendation
Action
Price target
Projected
Date
Taylor Conrad
Argus Research
Buy
Maintained
$11.00
+24.4%
08/10/2026
Unknown Analyst
Morgan Stanley
Buy
Maintained
$12.40
+40.2%
08/06/2026
Unknown Analyst
Berenberg Bank
Buy
Reiterated
$13.92
+57.4%
03/16/2026
Awaiting results...
Call Time: Thu, Oct 29, 5:00 AM
Fiscal period
Q3 2026
- / -
Revenue / Est. (GBP)
- / 2.90B
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in GBP
Loading Previous Earnings...
Revenue
Net income
All values in GBP
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
2.78B
2.78B
2.80B
2.80B
Cost of goods sold
970.50M
970.50M
949.50M
949.50M
Cost of revenue
970.50M
970.50M
949.50M
949.50M
Research and development expenses
81.50M
81.50M
73.50M
73.50M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1.08B
1.08B
1.11B
1.11B
Operating expense
1.16B
1.16B
1.18B
1.18B
Total operating expenses
2.13B
2.13B
2.13B
2.13B
Operating income
643.00M
643.00M
670.50M
670.50M
Other non operating income
-10.50M
-10.50M
1.50M
1.50M
EBT including unusual items
538.50M
538.50M
528.00M
528.00M
EBT excluding unusual items
552.00M
552.00M
612.50M
612.50M
Income tax expense
105.00M
105.00M
143.00M
143.00M
Effective tax rate
19.50%
19.50%
27.08%
27.08%
Other operating expenses
-
-
-
-
Net income
430.50M
430.50M
381.00M
381.00M
Net profit margin
15.51%
15.51%
13.60%
13.60%
Earnings per share
-
-
-
-
Interest and investment income
5.00M
5.00M
17.00M
17.00M
Interest expense
-85.50M
-85.50M
-76.50M
-76.50M
Net interest expenses
-80.50M
-80.50M
-59.50M
-59.50M
Depreciation and amortization charges
-
-
-
-
EBITDA
704.50M
704.50M
724.00M
724.00M
Gain or loss from assets sale
-
-
-10.00M
-10.00M
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps